Colorectal Cancer | Specialty

Adjuvant Treatment or "Watch and Wait" in Stage II CRC

July 10th 2019

Molecular Profiling in Stage II and III Colon Cancer

July 10th 2019

Adjuvant Therapy for Stage II and III Colon Cancer

July 10th 2019

Encorafenib, Binimetinib, and Cetuximab Regimen Improves Survival in BRAF+ CRC

July 6th 2019

Encorafenib, binimetinib, and cetuximab demonstrated a significant improvement in overall survival compared with cetuximab and an irinotecan-containing regimen in patients with BRAF-mutant colorectal cancer.

Published Data Back Regorafenib Dose Escalation in Colorectal Cancer

July 3rd 2019

A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer.

Dr. Lieu on Investigational Immunotherapy Strategies in mCRC

July 2nd 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).

Genome Sequencing Studies Shake Up Views on the Cancer Mutation Landscape

July 2nd 2019

Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.

TAS-102 Continues to Demonstrate Efficacy, Safety in CRC and Gastric Cancers

June 24th 2019

Howard S. Hochster, MD, provides insight into TAS-102 (trifluridine/tipiracil; Lonsurf) and highlights other important research being conducted in the colorectal cancer space.

Study Sheds Light on Incidence Patterns of Early-Onset CRC

June 24th 2019

Ana Acuna-Villaorduna, MD, provides further insight into the study that compares age and race as factors for the incidence of early-onset colorectal cancer.

Dr. Acuna-Villaorduna on the Increase of Early-Onset CRC Diagnoses

June 21st 2019

Ana Acuna-Villaorduna, MD, Heme/Oncology fellow at Montefiore Medical Center/Albert Einstein College of Medicine, discusses the increase of early-onset colorectal cancer, specifically in African-American and Hispanic populations.

Expanding the Use of Immunoscore in Early-Stage CRC

June 20th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses ways to expand the use of Immunoscore in early-stage colorectal cancer.

Dr. Lenz on Next Steps With Immunotherapy in mCRC

June 19th 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses next steps with immunotherapy in metastatic colorectal cancer.

Dr. Nallapareddy on the Use of ctDNA Testing in Colorectal Cancer

June 19th 2019

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist at Rocky Mountain Cancer Centers, discusses the use of circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC).

Pfizer Acquires Array BioPharma in $11.4 Billion Deal

June 18th 2019

Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.

Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC

June 17th 2019

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the tolerability of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

Tumor Sidedness Opens Door for Personalized Therapy in Colorectal Cancer

June 17th 2019

Sujatha Nallapareddy, MD, discusses how personalized therapy has improved the outlook for patients with colorectal cancer and sheds light on some of the challenges that lie ahead.

The Clinical Utility of Immunoscore in Stage III CRC

June 14th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses the prognostic value of Immunoscore in stage III colorectal cancer.

Dr. Lieu on HER2-Directed Therapy in CRC

June 14th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses HER2-directed therapy for patients with colorectal cancer (CRC).

Dr. Bekaii-Saab on the Impact of the BEACON CRC Study in BRAF-Mutated CRC

June 13th 2019

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of the BEACON CRC trial in patients with BRAF V600E-mutated metastatic colorectal cancer.

Future of mCRC Lies in Biomarker-Directed Therapies

June 12th 2019

Christopher Lieu, MD, highlights updates on biomarker-directed therapy with colorectal cancer and ongoing research being done with immunotherapy.